AAT Augmentation denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied AAT Augmentation as Experimental

Blue Cross Blue Shield applies an "experimental or investigational" (E&I) denial when it concludes that a treatment has not met its internal evidence threshold for coverage. For alpha-1 antitrypsin (AAT) augmentation therapy — used to treat AAT deficiency (AATD) — this denial can arise when BCBS determines that the clinical evidence base does not meet the specific standard in its coverage policy, or when there is a question about whether the treatment is being used for a covered indication.

This denial is notably strong grounds for appeal. AAT augmentation therapy has a well-established evidence base in the AATD literature, is supported by guidance from major pulmonary and rare-disease professional societies, and has received FDA licensure for relevant products. The appeal must engage directly with the specific evidence standard BCBS applied and demonstrate — with documented clinical evidence — that the standard is satisfied.

## Federal Appeal Rights

• ACA §2719 external review: E&I denials are among the most frequently overturned at external review. An Independent Review Organization reviews the medical evidence independently of BCBS. File within the deadline in your denial notice — typically around four months from the denial date per your plan documents.
• ERISA §503 (self-funded plans): BCBS must provide full and fair review with written explanation of the evidence standard applied and why it was not met.
• Expedited review: If interruption of ongoing AAT augmentation therapy poses a risk to lung function or health, request expedited processing simultaneously with standard appeal.

## Concrete Appeal Steps

1. Obtain BCBS's Coverage Medical Policy for AAT augmentation and identify the exact evidence standard and clinical criteria applied. 2. Request that BCBS identify the specific evidence gaps it found — this is required in the denial reasoning. 3. Have your prescriber, and ideally a pulmonologist or AATD specialist, draft a letter addressing the evidence standard directly, citing the applicable professional society guidelines (by organization name) and peer-reviewed literature supporting the use of AAT augmentation for your indication. 4. Submit an internal appeal within your plan's deadline with the documentation package below. 5. If denied internally, file for external review — and note that IROs apply objective clinical-evidence standards, not simply BCBS's internal coverage policy.

## Documentation to Gather

• Diagnosis confirmation: AATD diagnostic records, including genetic or serum testing confirming the deficiency (your prescriber will identify what is clinically relevant).
• Prior-treatment history: History of AATD management, including any treatments tried for the underlying lung disease, and the clinical course that led to initiation of augmentation therapy.
• Clinical-severity documentation: Pulmonary function test trends, imaging records, and chart notes documenting the severity of lung involvement.
• Specialist letter: A letter from the treating pulmonologist or AATD specialist that directly addresses the E&I determination, references the applicable professional society guideline organization, and explains why the evidence standard for coverage is met in this case.
• Published guideline references: Your specialist can identify the relevant pulmonary/rare-disease organizations that have issued guidance on AAT augmentation.

## Criteria-Mapping Structure

| BCBS Experimental-Determination Criterion | Evidence Rebutting the E&I Finding | |---|---| | Copy each evidence-standard criterion from the BCBS policy | Specialist letter paragraph, guideline organization citation, peer-reviewed literature reference | | Any indication-specific coverage requirement | Diagnostic records confirming the covered indication | | Any "accepted medical practice" standard | Professional society guideline organization's position on this therapy |

E&I denials for rare-disease therapies with established evidence bases are frequently reversed at external review. Document thoroughly and engage a specialist to lead the clinical argument.